Neurocognitive Outcomes of Children with Osteosarcoma Treated with
High-dose Intravenous Methotrexate
Methotrexate (MTX) has been shown to impair neurocognitive outcomes.
Because the cumulative dose of MTX used in the standard treatment of
osteosarcoma is higher compared to the treatment of other childhood
cancers, we analyzed the neurocognitive performance among 12 survivors
of childhood osteosarcoma exposed to high-dose MTX at our institution.
Prospective longitudinal evaluations of neurocognitive functioning using
the Japanese Wechsler Intelligence Scale for Children-4th Edition were
performed. As a result, we observed age-appropriate development of
neurocognitive performance among osteosarcoma survivors. In conclusion,
cognitive development was not adversely affected in this cohort of
childhood osteosarcoma survivors treated with HD-MTX.